Stem Cell Processing (Stem Cells in Clinical Applications)

119

Table 6.6 Kits and isolation systems for adipose tissue based on nonenzymatic methods currently
patented, published, or commercially available

No. Company Device/method

1 MicroAire Surgical Instruments,

LLC, USA

StromaCell™

2 Medikan International Inc., USA LipoKit GT

3 Lipogems International S.p.A.,

Italy

Lipogems ®

4 LifeCell Corporation, USA/GID

Group, Inc., USA

Revolve™/GID 700™

5 Genesis Biosystems, Inc., USA LipiVage™

6 CORIOS Soc. Coop., Italy Fastkit (Fastem)

7 Bimini Technologies LLC, USA Puregraft ®

8 Baxter International Inc., USA Devices for harvesting and

homogenizing adipose tissue

containing autologous endothelial

cells

9 MyStem LLC, USA MyStem ®

10 Regenm edlab Co. Ltd, Vietnam Cell Extraction Easy Kit

11 Agency Science, Tech & Res,

China

Method for isolating stromal

vascular fraction

12 Human Med AG, Germany Procedure and device for separating

adult stem cells from fatty tissue and

device for separating adult stem cells

13 IntelliCell BioSciences Inc.,

USA

Ultrasonic cavitation-derived stromal

or mesenchymal vascular extracts

and cells derived therefrom obtained

from adipose tissue and use thereof

and isolation of stromal vascular

fraction from vascular tissues

14 Pennington Biomedical

Research Center, USA

Nonenzymatic method for isolating

human adipose-derived stromal/stem

cells

15 Rusty Property Holdings Pty.

Ltd., Australia/Amberdale

Enterprises Pty. Ltd., Australia/

Tavid Pty., Australia

Isolation of stem cells from adipose

tissue by ultrasonic cavitation and

methods of use

16 Solta Medical, Inc., USA Selective lysing of cells using

ultrasound

FCS) with a high risk of disease transmission. Potential risks are also related to
allergies against xenoproteins and transmission of prions and viruses.
In the next generation of culture media for MSCs, FCS has been replaced by
human blood-derived products. Both autologous and xenogenic blood-derived
products have been successfully used for ex vivo culture of MSCs. Autologous
blood-based products are optimal for ex vivo culture of MSCs for clinical
application. However, it is sometimes detrimental for patients to undergo blood

6 Production of Clinical-Grade Mesenchymal Stem Cells